Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 15 posts of 212 posts found.

Eli Lilly shares results for tirzepatide for MASH resolution

June 10, 2024
Research and Development Eli Lilly, Hepatology, MASH, clinical trial, liver

Eli Lilly has announced results from the phase 2 SYNERGY-NASH study which assessed 190 patients, with or without type 2 …

News

Eli Lilly and UNICEF expand support for young people at risk of noncommunicable diseases

May 30, 2024
Medical Communications Eli Lilly, Pharmacy, Unicef, investment, noncommunicable diseases

Eli Lilly has announced that it will donate $6.5m to the United States Fund for UNICEF in order to expand …

News

Eli Lilly increases manufacturing investment to $9bn at new Indiana site

May 28, 2024
Manufacturing and Production Diabetes, Eli Lilly, Indiana, investment, manufacturing

Eli Lilly has announced that it has more than doubled its investment at its Lebanon, Indiana, US manufacturing site with …

News

Eli Lilly shares positive results from phase 3 VIVID-1 trial of Crohn’s disease treatment

May 22, 2024
Medical Communications Crohn’s disease, Eli Lilly, Endocrinology, clinical trial, mirikizumab

Eli Lilly has announced results from its pivotal phase 3 VIVID-1 study, which assessed patients with moderately to severely active …

News

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024
Manufacturing and Production Eli Lilly, Nexus Pharmaceuticals, Pharmacy, acquisition, facility

Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement for Eli Lilly to acquire …

News

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024
Research and Development Ear Nose & throat, Eli Lilly, clinical trial, sleep apnoea, tirzepatide

Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated that tizepatide injection (10mg or …

News

Zuellig Pharma acquires Cialis and Alimta from Eli Lilly in certain ASEAN markets

February 5, 2024
Business Services Cialis, Eli Lilly, Pharmacy, Zuellig Pharma, acquisition

Zuellig Pharma has announced that it has completed the acquisition of two brands Cialis (Tadalafil) and Alita (Pemetrexed) from Eli …

News

Isomorphic Labs to collaborate with Eli Lilly

January 11, 2024
Research and Development AI, Eli Lilly, Isomorphic Labs, Pharmacy, drug discovery

Isomorphic Labs has announced that it has entered into a strategic research collaboration with Eli Lilly and Company, marking the …

News
national-cancer-institute-l8twzt4ccvq-unsplash_1

Eli Lilly launches digital healthcare process

January 5, 2024
Medical Communications Diabetes, Eli Lilly, Obesity, diabetes, obesity

Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine …

News

Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment

December 4, 2023
Medical Communications Eli Lilly, FDA, Jaypirca, Oncology, leukaemia, lymphoma

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100mg and 50mg tablets) …

News

Eli Lilly’s Zepbound approved by FDA for chronic weight management

November 9, 2023
Medical Communications Eli Lilly, FDA, Obesity, Zepbound, weight loss, weight management

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) injection for chronic weight …

News

Eli Lilly’s Omvoh receives FDA approval for ulcerative colitis treatment

October 27, 2023
Medical Communications Eli Lilly, FDA, Gastrointestinal tract, Omvoh, ulcerative colitis

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) infusion (300mg/15mL)/injection (100mg/mL) for …

News

Eli Lilly to acquire POINT Biopharma

October 4, 2023
Business Services Eli Lilly, Oncology, POINT Biopharma, acquisition, oncology

Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT to expand its pipeline of …

News

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

September 25, 2023
Medical Communications Boehringer Ingelheim, Eli Lilly, FDA, Nephrology, chronic kidney disease

Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10mg …

News

Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

August 23, 2023
Research and Development Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancer

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with …

News

Latest content

CytoSorbents announces EU launch and availability of PuriFi blood pump

June 14, 2024

AbbVie and FutureGen announce license agreement for IBD therapy

June 14, 2024

Pfizer shares update on DMD gene therapy clinical trial

June 13, 2024

Cara Therapeutics shares data from part a of notalgia paresthetica trial

June 13, 2024

Tracon shares data from phase 2 trial for glioblastoma treatment

June 12, 2024